An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes.
about
Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of EfficacyUpdate on optimal use of lisdexamfetamine in the treatment of ADHD.New and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children.Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry.Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover StudyAn open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder.Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.The use of lisdexamfetamine dimesylate for the treatment of ADHD.Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells.The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder.The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs.
P2860
Q26750486-CE619286-CF6D-46B9-BCBE-C18ABC84853DQ30418053-F23A2333-73D9-45B1-957D-300DA20813CEQ33881547-831B06CC-FFA3-460C-918E-3430F09A5A03Q34032634-C9FB0364-AACA-43B6-8239-8DA96256104AQ34232286-39C26818-D1EA-45CE-A8EE-9F180C72E137Q35807351-564C62A8-D630-498F-B941-0ADAE1302B60Q36718468-3C6BEAA5-445D-4946-967E-CDF6FFB69871Q36947618-4DD59257-949B-49AD-A6CB-743AC43A969CQ37422844-8C43830B-B418-489A-8941-A1544A67AEA1Q37561623-00CA0F4A-498F-4BBB-87AB-775B48D08B02Q37803420-AB110D3F-6180-4BE2-A1C4-01F465594D3FQ37975550-33EF82A3-1B21-4A57-A78E-059E2A373727Q38011640-97CA1381-DD8F-47E7-984F-8CC86C641202Q41833735-1DE0AC0B-F332-4899-838A-43E139318B15Q46535632-DBAE95A8-614A-450B-AE4D-CA15880EAD56Q47598246-54F3A47C-9540-426F-8BDD-6F0A29C7EE70
P2860
An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
An evaluation of the cytochrom ...... ine in human liver microsomes.
@en
An evaluation of the cytochrom ...... ine in human liver microsomes.
@nl
type
label
An evaluation of the cytochrom ...... ine in human liver microsomes.
@en
An evaluation of the cytochrom ...... ine in human liver microsomes.
@nl
prefLabel
An evaluation of the cytochrom ...... ine in human liver microsomes.
@en
An evaluation of the cytochrom ...... ine in human liver microsomes.
@nl
P356
P1476
An evaluation of the cytochrom ...... ine in human liver microsomes.
@en
P2093
Scott Moncrief
Suma Krishnan
P304
P356
10.1124/DMD.106.011973
P577
2006-10-11T00:00:00Z